암 유전자 치료 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Cancer Gene Therapy Market size is expected to reach USD 29.86 Billion in 2034 from USD 6.16 Billion (2025) growing at a CAGR of 19.17% during 2026-2034.

The Global Cancer Gene Therapy Market is witnessing rapid growth due to advancements in molecular biology and genetic engineering. Increasing prevalence of cancer worldwide has accelerated research in innovative treatment approaches. Gene therapy offers targeted solutions by modifying or replacing defective genes, improving treatment precision. Rising investments in oncology research and clinical trials are significantly supporting market development.

Key growth drivers include breakthroughs in viral vector technology and CRISPR-based gene editing tools. Expanding adoption of personalized medicine enhances the demand for gene-based therapies. Regulatory approvals of novel gene therapies encourage further innovation. Additionally, collaborations between biotechnology firms and research institutions accelerate product commercialization and market expansion.

Looking ahead, the market is expected to grow with ongoing advancements in delivery systems and safety profiles. Increased awareness and improved reimbursement frameworks will facilitate adoption. Emerging markets with expanding oncology infrastructure present new opportunities. As research continues to refine gene-editing technologies, cancer gene therapy is poised to become a transformative force in oncology treatment.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product Therapy

• Oncolytic Virotherapy
• Gene Induced Immunotherapy
• Gene Transfer

By End Use

• Research Institutes
• Biopharmaceutical Companies
• Diagnostic Centers
• Others

COMPANIES PROFILED

• Abeona Therapeutics Inc, Asklepios BioPharmaceutical Inc, Altor Bioscience Corp, Bluebird Bio Inc, BioCancell Therapeutics Inc, Celgene Corporation, Elevate Bio Inc, GlaxoSmithKline plc, Genelux Corporation, GenVec Inc, Introgen Therapeutics Inc, Merck KGaA, OncoGenex Pharmaceuticals Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CANCER GENE THERAPY MARKET: BY PRODUCT THERAPY 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product Therapy
• 4.2. Oncolytic Virotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Gene Induced Immunotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Gene Transfer Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CANCER GENE THERAPY MARKET: BY END USE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast End Use
• 5.2. Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Biopharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Diagnostic Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CANCER GENE THERAPY MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Product Therapy
  • 6.2.2 By End Use
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Product Therapy
  • 6.3.2 By End Use
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Product Therapy
  • 6.4.2 By End Use
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Product Therapy
  • 6.5.2 By End Use
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Product Therapy
  • 6.6.2 By End Use
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL CANCER GENE THERAPY INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Abeona Therapeutics Inc
  • 8.2.2 Asklepios BioPharmaceutical Inc
  • 8.2.3 Altor Bioscience Corp
  • 8.2.4 Bluebird Bio Inc
  • 8.2.5 BioCancell Therapeutics Inc
  • 8.2.6 Celgene Corporation
  • 8.2.7 Elevate Bio Inc
  • 8.2.8 GlaxoSmithKline Plc
  • 8.2.9 Genelux Corporation
  • 8.2.10 GenVec Inc
  • 8.2.11 Introgen Therapeutics Inc
  • 8.2.12 Merck KGaA
  • 8.2.13 OncoGenex Pharmaceuticals Inc